Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC – Get Rating) have earned an average rating of “Moderate Buy” from the six research firms that are  covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and three have assigned  a buy recommendation to  the company. The average 1 year price objective among brokers that have covered the stock in the last year is $92.33.

GEHC has been the topic of several recent analyst reports. Edward Jones assumed coverage on shares of GE HealthCare Technologies in a research note on Wednesday, January 4th. They set a “hold” rating on the stock. Redburn Partners started coverage on GE HealthCare Technologies in a research note on Thursday, January 19th. They set a “buy” rating for the company. BTIG Research assumed coverage on shares of GE HealthCare Technologies in a research note on Monday, April 10th. They issued a “neutral” rating on the stock. Piper Sandler assumed coverage on shares of GE HealthCare Technologies in a research report on Wednesday. They set an “overweight” rating and a $95.00 price objective for the company. Finally, Evercore ISI began coverage on shares of GE HealthCare Technologies in a research report on Monday, March 13th. They issued an “outperform” rating and a $90.00 target price on the stock.

In related news, Director H Lawrence Culp, Jr. bought 748 shares of the stock in a transaction on Monday, January 23rd. The stock was bought at an average price of $69.26 per share, with a total value of $51,806.48. Following the completion of the purchase, the director now directly owns 1,272 shares in the company, valued at approximately $88,098.72. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director H Lawrence Culp, Jr. bought 748 shares of the company’s stock in a transaction on Monday, January 23rd. The stock was bought at an average cost of $69.26 per share, with a total value of $51,806.48. Following the transaction, the director now directly owns 1,272 shares in the company, valued at approximately $88,098.72. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jan Makela sold 70,629 shares of the business’s stock in a transaction dated Tuesday, March 14th. The stock was sold at an average price of $77.69, for a total transaction of $5,487,167.01. Following the sale, the chief executive officer now owns 63,796 shares in the company, valued at $4,956,311.24. The disclosure for this sale can be found here. 0.21% of the stock is owned by insiders.

Shares of GEHC opened at $83.66 on Wednesday. The stock’s 50-day moving average is $76.64. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.86 and a current ratio of 1.16. GE HealthCare Technologies has a fifty-two week low of $53.00 and a fifty-two week high of $84.16.

GE HealthCare Technologies (NASDAQ:GEHC – Get Rating) last announced its quarterly earnings results on Monday, January 30th. The company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.25. The company had revenue of $4.94 billion during the quarter, compared to analyst estimates of $4.80 billion. GE HealthCare Technologies’s revenue was up 7.6% compared to the same quarter last year.  On average, analysts anticipate that  GE HealthCare Technologies will post 3.7 earnings per share for the current fiscal year.

GE HealthCare Technologies Inc provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is based in Chicago, Illinois.

Receive News & Ratings for GE HealthCare Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GE HealthCare Technologies and related companies with MarketBeat.com's FREE daily email newsletter.